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PNM25
DRUG PERSISTENCE PATTERNS SIMILAR FOR
RIVASTIGMINE-TREATED PATIENTS AND
DONEPEZIL-TREATED PATIENTS
Mauskopf J1, Paramore C2, Lee WC2, Snyder EH3
1RTI Health Solutions, Kansas, NC, USA; 2MEDTAP
International, Bethesda, MD, USA; 3Novartis Pharmaceuticals,
East Hanover, NJ, USA
OBJECTIVE: To assess “real world” drug persistence
patterns for patients with Alzheimer’s Disease (AD)
treated with clinically effective doses of rivastigmine or
donepezil by evaluating rates of discontinuation and
change in therapy. METHODS: A retrospective cohort
study was conducted using longitudinal pharmacy claims
data from the PharMetrics Patient-Centric database.
Newly treated, US, community-based AD patients were
identiﬁed as having an initial prescription (index event)
for rivastigmine or donepezil between June and Decem-
ber, 2000. Patients receiving either drug during the 180
days prior to their index prescription or who did not have
continuous plan enrollment during this period were
excluded. Patients reaching clinically effective doses 
of donepezil (5..C10mg/day) or rivastigmine (6..C12
mg/day), and undergoing ≥ 60 days continuous therapy
were analyzed. The primary outcome measure was time
to treatment failure, deﬁned as either discontinuation of
therapy (no prescription reﬁll within 90 days of estimated
completion of prior prescription) or switch to alternative
AD drug. Kaplan-Meier survival and proportional hazard
model analyses were performed. RESULTS: A total of
1650 AD patients treated with rivastigmine or donepezil
met all study eligibility criteria and reached clinically
effective doses. Treatment failure occurred for 66% of
donepezil patients (27% within ﬁrst 60 days) and 60%
of rivastigmine patients (20% within ﬁrst 60 days) during
the approximate 1-year follow-up. The mean (95% CI)
time to failure was 360 (332..C398) days for the rivastig-
mine group versus 376 (361..C391) days for donepezil 
(p = 0.083). In patients receiving the maximum recom-
mended doses, mean time to treatment failure was 392
(372..C412) days with donepezil 10mg/day versus 403
(352..C454) days for rivastigmine 12mg/day (p = 0.24).
CONCLUSIONS: Drug persistence patterns were similar
for rivastigmine and donepezil patients who reach a clin-
ically effective dose, but there was a trend in favor of
rivastigmine for patients reaching higher doses.
PNM26
STANDARD GAMBLE TECHNIQUE—A TOOL TO
ASSESS QUALITY OF LIFE IN PATIENTS WITH
EPILEPSY
Dolan P1, Chandler F2, Behrens M2, Baxter C2
1University of Shefﬁeld, Shefﬁeld, United Kingdom;
2GlaxoSmithKline, Uxbridge, United Kingdom
OBJECTIVE: Epilepsy treatment and associated side-
effects have signiﬁcant impact on patients’ health-related
quality of life (HRQoL). Literature suggests that generic
tools (eg EQ-5D) are not appropriate in epilepsy. This
analysis assesses impact on HRQoL of three common
anti-epileptic drugs using standard gamble (SG) tech-
nique. METHOD: A questionnaire was administered to
65 members of the public without epilepsy (age 18–86)
deriving scores for seven health states. Health states cor-
responded to epilepsy treatment side-effect proﬁles and
associated occurrence probabilities with monotherapy:
sodium valproate/VPA [weight gain (30%), hair loss
(10%), body hair growth], lamotrigine/LTG [rash (10%)]
and carbamazepine/CBZ [lack of concentration (10%),
perceived impaired intelligence by others]. Questionnaire
for women of childbearing potential/WCBP (aged 18–45)
included failure of oral contraception and possibilities 
of foetal abnormalities (CBZ). Utility scores were derived
using standard methodology. RESULTS: Sixty-four
respondents completed the exercise: 46 female (17
WCBP), 18 male; average age 51.7 years. None had
epilepsy; 10 had a family member with epilepsy. Respon-
dents’ utility values [mean (SD)]: 1. Patients controlled:
LTG 0.751 (0.300), VPA 0.748 (0.307), CBZ 0.712
(0.338); 2. Patients partially controlled: LTG 0.743
(0.308), VPA 0.706 (0.322), CBZ 0.689 (0.340). Uncon-
trolled epilepsy (no treatment) was valued at 0.571 (SD
0.380). Utility values for WCBP with partial control were
higher for LTG (0.837; SD 0.236) versus CBZ (0.658; SD
0.359) and VPA (0.702; SD 0.314). Utilities for treat-
ments yielding full control were higher than those with
partial control. Results are in line with published data 
on epilepsy. Testing showed no signiﬁcant differences
between respondent sub-groups on any domain. CON-
CLUSION: Results indicate that both seizure control and
treatment side-effects affect utility. SG is a valuable
methodology for deriving utilities in epilepsy (compared
to generic instruments) for cost-effectiveness analyses
(CEA). Applying ﬁndings to a decision-tree CEA yielded
£13,045/QALY (range £8,928–£18,960) for lamotrigine
over sodium valproate and carbamazepine.
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SCLEROSIS (FAMS): EVALUATING THE
LINGUISTIC VALIDITY OF 5 NEW LANGUAGES:
PORTUGUESE, JAPANESE, HEBREW, RUSSIAN,
AND KOREAN
Eremenco S1, Kaskel P2, de Sa J3, Fukaura H4, Miller A5,
Cella D1
1Evanston Northwestern Health care, Evanston, IL, USA;
2Schering, Berlin, Germany; 3Hospital Santa Maria, Lisbon,
Portugal; 4Hokkaido University Hospital, Sapporo, Japan;
5Carmel Hospital, Haifa, Israel
OBJECTIVE: To evaluate the performance of newly-
translated Portuguese, Japanese, Hebrew, Russian, and
Korean FAMS questionnaires. METHODS: Using both
qualitative and quantitative data, we assessed the prelim-
inary psychometric properties of the translations. The
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translation methodology included two forward transla-
tions by native speakers in each language, a reconciled
version of the two forwards by a third translator, back-
translation of the reconciled version by a native English
speaker ﬂuent in the target language, and three indepen-
dent reviews by native speaking experts. Retrospective
debrieﬁng interviews were conducted in which 113
patients (20 in Portugal, 20 in Japan, 19 in Brazil, 34 in
Israel, and 20 in Korea) diagnosed with multiple sclero-
sis were asked to read and answer the questionnaire in
Portuguese, Japanese, Hebrew, Russian, or Korean and
then give their opinion on any problems with the trans-
lation or the content of the questionnaire. Statistical
analyses (descriptive statistics and reliability analyses)
were performed on the quantitative data, and the partic-
ipant comments were reviewed. RESULTS: Age range
was 19 to 64 years; there were 75 women and 38 men.
The FAMS performed very well in all target languages.
Cronbach’s alpha coefﬁcients for total FAMS were high
(range = 0.93–0.96), indicating overall scale homogene-
ity comparable to the original English version. Based
upon statistical analyses and comments from patients, no
revisions were necessary for the Portuguese, Japanese,
Russian, and Korean translations. However, two revi-
sions were made to the Hebrew version as a result of data
collected during testing. CONCLUSIONS: Participants
were comfortable with the questionnaire and felt that the
questions addressed issues important to multiple sclero-
sis. The ﬁnal versions of the Portuguese, Japanese,
Hebrew, Russian, and Korean FAMS are linguistically
acceptable and show good psychometric performance,
and are now ready for inclusion in clinical trials and other
research studies to evaluate the quality of life of patients
with multiple sclerosis.
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PAIN—Clinical Outcomes Studies
PPN1
TOPIRAMATE FOR THE TREATMENT OF
PERIPHERAL DIABETIC NEUROPATHY:
CANADIAN CLINICAL EXPERIENCE
Hwang P1, Brock I2
1Janssen-Ortho Inc,Toronto, ON, Canada; 2Research One
International, Lachine, QC, Canada
OBJECTIVE: The complexity of peripheral diabetic 
neuropathy (PDN) and the highly variable effects of indi-
vidual drugs mean that clinicians continue to seek alter-
natives for their patients. The objective of this study was
to evaluate and describe the use of topiramate for PDN
in Canadian clinical practice. METHODS: Retrospective
review of 100 patient charts using physician interview.
Physicians were asked to include the 4 most recent
patients that met the following criteria: 1) diagnosis of
PDN; 2) topiramate started ≥6 months prior to review
date to allow an adequate trial time for drug therapy; 3)
no concomitant gabapentin use. RESULTS: Patient char-
acteristics: 8% Type 1 diabetes, 92% Type 2; mean age
55.4 years; 45% male; 85% Caucasian; 61% with
medical conditions other than diabetes /PDN requiring
drug therapy. Pain distribution: foot/toe 91%, calf 29%,
ﬁnger/hand 28%, thigh 19%. Pain quality: burning 55%,
tingling 47%, pins and needles 30%, aching 23%, sharp
19%, cramping 17%, jabbing 17%, shooting 17%. Top-
iramate therapy: mean duration 14.4 months; mean total
daily dose 136mg. 98% were current users. Patients had
PDN for 21.5 months on average prior to starting topi-
ramate therapy. Topiramate was used as monotherapy in
79%. In 59% topiramate was the ﬁrst-line drug. 24%
experienced topiramate-related adverse effects (AEs);
most common: dizziness 29%, somnolence 21%, nausea
17%, and numbness 13%. Actions taken for AEs: none
(71%), dose reduction (17%), slower titration (13%),
treatment with another drug (4%). According to physi-
cian assessment, 64% (95%CI 46, 82) were “very much
improved” or “much improved” for pain, 49% (95%CI
30, 68) for physical activity, and 51% (95%CI 33, 70)
for sleep. CONCLUSIONS: Under conditions of routine
clinical care, topiramate was effective in relieving pain
and improving physical activity and sleep in patients with
PDN. Most patients tolerated the drug long-term with no
discontinuation of therapy resulting from AEs.
PPN2
TOPIRAMATE IS EFFECTIVE IN PATIENTS WITH
PERIPHERAL DIABETIC NEUROPATHY FOR
WHOM OTHER ANTICONVULSANTS HAVE
FAILED
Hwang P1, Brock I2
1Janssen-Ortho Inc,Toronto, ON, Canada; 2Research One
International, Lachine, QC, Canada
OBJECTIVE: Neuropathic pain is difﬁcult to manage and
pharmacotherapy is often unsatisfactory. Patients often
will have tried a large number of drugs in an effort to ﬁnd
relief. This study evaluated the effectiveness and safety of
topiramate in patients with peripheral diabetic neuropa-
thy (PDN) who have previously tried other anticonvul-
sants. METHODS: Retrospective review of 100 patient
charts using physician interview. Physicians were asked to
include the 4 most recent patients that met the following
criteria: 1) diagnosis of PDN; 2) topiramate started ≥6
months prior to review date to allow an adequate trial
time for drug therapy; 3) no concomitant gabapentin use.
A subgroup of 28 patients that had failed other anticon-
vulsants prior to topiramate was analyzed. RESULTS:
Patient characteristics: 14% Type 1 diabetes, 86% Type
2; mean age 64.9 years; 54% males; 93% Caucasian.
Most commonly affected areas: foot/toe (82%), calf
(36%), ﬁnger/hand (32%), thigh (21%). Most common
qualities: burning (57%), tingling (50%), aching (46%),
pins and needles (21%). Previous anticonvulsants
included gabapentin (82%), carbamazepine (29%), clon-
azepam (4%), and divalproex (4%). The most common
